...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of women’s health >Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations
【24h】

Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations

机译：在澳大利亚和曼尼托巴，加拿大的预定更年期激素治疗和双膦酸盐的趋势，并遵守推荐

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Recommendations for using menopausal hormone therapy (MHT) and bisphosphonates for postmenopausal osteoporosis management have changed over time. After the release of the Women's Health Initiative (WHI) trial results in 2002, new evidence on risks and benefits of MHT became available, and newer guidelines generally specify that MHT should not be prescribed for prevention of chronic disease, including osteoporosis. This raises the question of whether bisphosphonate prescribing changed over time to compensate for the decrease in MHT use. Materials and Methods: We examined trends in dispensed prescriptions in Australia (national) and Canada (province of Manitoba) in relation to prescribing recommendations. Administrative data were used to describe dispensing patterns and changes for persons of all ages from 1996 to 2008, and for women aged 50 to >= 80 years from 2003 to 2008 in Australia and 1996 to 2008 in Canada. Results: In both geographic settings, MHT dispensing increased 1996-2001, peaked in 2001, and declined substantially thereafter (67% reduction in MHT prescriptions for Australia; 64% reduction for Manitoba, Canada to 2008). From 2003 to 2008, the number of MHT prescriptions declined among all age groups in both settings, with the highest declines among women in their 50s. Concurrently, bisphosphonate dispensing increased until 2005 (2001-2005: 260% increase in the number of prescriptions in Australia; 125% increase in Manitoba) and stabilized thereafter, in both settings. Annual bisphosphonate dispensing rates increased 4.1-10.9% for women in their 70s and 80s in Australia and Manitoba during the period studied. Conclusions: Based on dispensed prescriptions data, more recent guidelines for MHT and bisphosphonates use for postmenopausal osteoporosis, which were updated during the study period (and are still consistent with the current guidelines), appear to have been broadly adhered to in both settings.
机译：背景技术：用于绝经后骨质疏松症管理的使用寿命素治疗（MHT）和双膦酸盐的建议随着时间的推移而变化。在释放妇女的健康倡议（WHI）试验结果2002年后，有关MHT的风险和福利的新证据可用，较新的指导方针通常指出不应规定预防慢性疾病，包括骨质疏松症的MHT。这提出了双膦酸酯规定的问题随着时间的推移而改变，以补偿MHT使用的降低。材料与方法：我们在规定建议中审查了澳大利亚（国家）和加拿大（曼尼托巴省）分配处方的趋势。行政数据用于描述1996年至2008年的所有年龄段的分配模式和变化，以及从2003年到2008年的50岁至2008年的妇女在澳大利亚和1996年到2008年在加拿大。结果：在地理设置中，MHT分配量增加了1996 - 2001年，2001年达到峰值，此后大幅下降（澳大利亚MHT处方减少67％;加拿大Manitoba减少64％）。从2003年到2008年，两种环境中所有年龄段的MHT处方都下降，50岁的女性下降最高。同时，双膦酸盐分配增加至2005年（2001-2005：澳大利亚处方数量增加260％;曼尼托巴巴增加125％），此后在两个环境中稳定。在研究期间，在澳大利亚和80年代的妇女在研究期间，每年的双膦酸盐分配率增加了4.1-10.9％。结论：基于分配的处方数据，在研究期间更新的MHT和Bisphossonate用于绝经后骨质疏松症的更新指南（并且仍然与当前指南一致），似乎在这两种环境中被广泛地遵守。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号